Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.47 |
| ▸ | MTOR | P42345 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11851842 | 0.87 | KMT2A (0.70) | KMT2AHTTALDH1A1LMNANPSR1 | |
| SCHEMBL11305784 | 0.84 | CASP1 (0.39) | KMT2AHTTKDM4ENPSR1HRH4 | |
| SCHEMBL3997510 | 0.82 | POLB (0.52) | KMT2AHTTKDM4EALDH1A1PIK3CA | |
| SCHEMBL8973821 | 0.81 | HTT (0.63) | KMT2AHTTKDM4EALDH1A1PIK3CA | |
| SCHEMBL28326273 | 0.80 | KDM4E (0.53) | KMT2AHTTKDM4EALDH1A1PIK3CA | |
| SCHEMBL11742121 | 0.80 | LMNA (0.67) | HTTKDM4EALDH1A1PIK3CALMNA | |
| SCHEMBL2805776 | 0.79 | CASP1 (0.50) | KMT2AHTTKDM4EALDH1A1LMNA | |
| SCHEMBL3876609 | 0.79 | KMT2A (0.51) | KMT2AHTTKDM4EALDH1A1PIK3CA | |
| SCHEMBL9418611 | 0.79 | HTT (0.61) | KMT2AHTTKDM4EALDH1A1PIK3CA | |
| SCHEMBL9003193 | 0.78 | KMT2A (0.76) | KMT2AHTTKDM4EALDH1A1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309221-A1 | METHOD OF INHIBITING HAMARTOMA TUMOR CELLS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-8563549-B2 | Pyrimidine derivatives used as PI-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-8563549-B2 | Pyrimidine derivatives used as PI-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-8563549-B2 | Pyrimidine derivatives used as PI-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| CN-102952086-B | Preparation method of 2-morpholinyl-substituted pyrimidine compounds | TIANJIN SCIPHARMACN LTD | 2013-08-28 | — | — | CN | disclosed |
| EP-2261223-B1 | Pyrimidine derivatives used as pi-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-06-12 | — | — | EP | disclosed |
| EP-2261223-B1 | Pyrimidine derivatives used as pi-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-06-12 | — | — | EP | disclosed |
| CN-102952086-A | Preparation method of 2-morpholinyl-substituted pyrimidine compounds | TIANJIN SCIPHARMACN LTD | 2013-03-06 | — | — | CN | disclosed |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1984350-B1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-08-18 | — | — | EP | disclosed |
| EP-1984350-B1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009066084-A1 | 2 -MORPHOLINOPYRIMIDINES AND THEIR USE AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-05-28 | — | — | WO | disclosed |
| EP-1984350-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | Novartis AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| EP-0185778-A1 | Method and composition for enhancing the insecticidal activity of certain organophosphorus compounds | THE DOW CHEMICAL COMPANY (US) | 1986-07-02 | — | — | EP | disclosed |
| US-4489068-A | Method and composition for enhancing the insecticidal activity of certain organophosphorus compounds | THE DOW CHEMICAL COMPANY (US) | 1984-12-18 | — | — | US | disclosed |
| US-4107301-A | INSECTICIDES, ACARICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | PIK3CA, PI4KA, PI4KB | KMT2A 2616/4885HTT 4458/4885KDM4E 3247/4885 |
| US-20140309221-A1 | METHOD OF INHIBITING HAMARTOMA TUMOR CELLS | PHPT1, VHL, SDHA | KMT2A 721/4885HTT 1321/4885KDM4E 1633/4885 |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | PIK3CA, PI4KA, PI4KB | KMT2A 2718/4885HTT 4468/4885KDM4E 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.